Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 3
2007 1
2008 3
2009 6
2010 2
2012 3
2013 1
2014 1
2015 2
2017 3
2018 3
2019 1
2020 1
2021 3
2022 7
2023 6
2025 3
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.
Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, Muller WJ, Zar HJ, Brooks D, Grenham A, Wählby Hamrén U, Mankad VS, Ren P, Takas T, Abram ME, Leach A, Griffin MP, Villafana T; MELODY Study Group. Hammitt LL, et al. N Engl J Med. 2022 Mar 3;386(9):837-846. doi: 10.1056/NEJMoa2110275. N Engl J Med. 2022. PMID: 35235726 Clinical Trial.
Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity.
Domachowske J, Madhi SA, Simões EAF, Atanasova V, Cabañas F, Furuno K, Garcia-Garcia ML, Grantina I, Nguyen KA, Brooks D, Chang Y, Leach A, Takas T, Yuan Y, Griffin MP, Mankad VS, Villafana T; MEDLEY Study Group. Domachowske J, et al. N Engl J Med. 2022 Mar 3;386(9):892-894. doi: 10.1056/NEJMc2112186. N Engl J Med. 2022. PMID: 35235733 Clinical Trial. No abstract available.
Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants.
Muller WJ, Madhi SA, Seoane Nuñez B, Baca Cots M, Bosheva M, Dagan R, Hammitt LL, Llapur CJ, Novoa JM, Saez Llorens X, Grenham A, Kelly EJ, Mankad VS, Shroff M, Takas T, Leach A, Villafana T; MELODY Study Group. Muller WJ, et al. N Engl J Med. 2023 Apr 20;388(16):1533-1534. doi: 10.1056/NEJMc2214773. Epub 2023 Apr 5. N Engl J Med. 2023. PMID: 37018470 No abstract available.
Immunogenicity and safety of a pentavalent meningococcal MenABCWY vaccine in healthy adolescents and young adults: a phase 3, multicountry, randomised, observer-blinded, active-controlled non-inferiority trial.
Ostergaard L, Czajka H, Roque-Guerrero L, Maguire JD, Pregaldien JL, Zolotas L, Moughan B, Maansson R, O'Neil R, Balmer P, Jodar L, Gruber WC, Anderson AS, Scott DA, Beeslaar J. Ostergaard L, et al. Among authors: czajka h. Lancet Child Adolesc Health. 2026 Aug;10(8):584-596. doi: 10.1016/S2352-4642(26)00095-7. Epub 2026 Jun 18. Lancet Child Adolesc Health. 2026. PMID: 42314722 Clinical Trial.
New Insights on Respiratory Syncytial Virus Prevention.
Kopera E, Czajka H, Zapolnik P, Mazur A. Kopera E, et al. Among authors: czajka h. Vaccines (Basel). 2023 Nov 30;11(12):1797. doi: 10.3390/vaccines11121797. Vaccines (Basel). 2023. PMID: 38140201 Free PMC article. Review.
[Controversies around vaccinations].
Szenborn L, Czajka H, Wysocki J. Szenborn L, et al. Among authors: czajka h. Przegl Lek. 2009;66(1-2):65-71. Przegl Lek. 2009. PMID: 19485260 Review. Polish.
46 results